Business Wire

BOEHRINGER-INGELHEIM

Del
New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries

Boehringer Ingelheim today announced regulatory authority approvals for Spiolto® Respimat® (tiotropium/olodaterol) in first European countries . Spiolto® Respimat® is a once-daily maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Approvals of the treatment in other European countries are expected to follow in the coming months. Spiolto® Respimat® provides significant improvements in lung function, breathlessness, quality of life and rescue medication use over Spiriva® right from the initial stages when patients need maintenance therapy.1 These additional benefits could enable patients to remain active and avoid the downward spiral of COPD for as long as possible.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150701006479/en/

COPD is a chronic, progressive, treatable but incurable lung disease that affects 210 million people worldwide4 and is predicted to become the 3rd leading cause of death by 2030.5 Patients are typically diagnosed when lung function is already significantly impaired and maintenance therapy is needed.6 They suffer from symptoms including breathlessness and coughing that often stop them from being active. This can lead to a downward spiral of worsening symptoms and even further inactivity,7 contributing to an increased risk of disability and death.8

“The additional benefits gained from Spiolto® Respimat® compared to Spiriva® are significant for patients and data show the lung function benefits are even greater when used in the initial stages of COPD. It is a promising new therapeutic advance in COPD,” said Roland Buhl, Professor of Medicine and Head of the Pulmonary Department at Mainz University Hospital. “Optimal management right from the start of maintenance therapy may give patients with this highly debilitating lung disease, the best opportunity to stay active, manage their symptoms and have a better quality of life.”

The national regulatory approvals, following finalisation of the decentralised European regulatory procedure on 20th May, are based on data from the >5,000 patient TONADO® 1&2 clinical trials. The TONADO® trials are part of the >15,000 patient TOviTO® clinical trial programme which shows Spiolto® Respimat® provides clinically relevant improvements over Spiriva®ǂ :

  • Significant improvement in lung function* , with greatest benefit seen in patients who are at the first stage of needing maintenance therapy for their COPD3 – and more than double the improvement in lung function* in patients who had no prior maintenance therapy§ (148ml vs. 72ml)2
  • Reduction in breathlessness and less use of rescue medication among patients1 (22% and 26% improvement in use of daytime and night-time rescue medication over Spiriva® respectively)
  • More patients experiencing noticeable improvements in their quality of life (57.5% vs 48.7%)1
  • Spiolto® Respimat® was well tolerated with a safety profile that was similar to tiotropium or olodaterol alone1

“Since its first launch in 2002, Spiriva® has brought medical benefits that have made a real difference to the lives of millions of patients with COPD around the world. Spiolto® Respimat® is our newest advance in COPD treatment. Its recent approval in the US** , Canada and Australia, alongside the approval in countries across Europe, is an important step forward in our ongoing commitment to provide effective solutions for patients with COPD,” said Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “We anticipate further approvals of Spiolto® Respimat® in other European countries over the coming months.”

Spiolto® Respimat® is built on tiotropium, the active ingredient in Spiriva® - the world’s most prescribed COPD maintenance treatment with over 40 million patient years of real life experience across all COPD severities.9 It is enhanced by olodaterol†† , a unique and effective long-acting beta2-agonist with a fast onset of action, specifically designed to complement the efficacy of Spiriva® . Spiolto® is delivered by Respimat® , the only inhaler available that activelyǂǂ delivers a unique mist, meaning the patient just needs to breathe in naturally for the medication to go deep into the lungs.10-16

Intended audiences

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For ‘Notes to Editors’ and ‘References’ please visit: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/02_july_2015_copd.html

* Improvement in trough FEV1 after 24 weeks of treatment

As of Monday 29th June, Spiolto® Respimat® has been approved in Croatia, United Kingdom, Slovakia, Denmark, Norway, Ireland, Austria, Romania and Spain

ǂ The data in this press release refer to Spiolto® Respimat® 5/5µg dose which is the dose approved by regulatory authorities

§ Patients without prior maintenance therapy at baseline

** Registered as Stiolto Respimat® in the US

†† Marketed as Striverdi® Respimat®

ǂǂ Respimat® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient’s inhalation

Contact:

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr Kristin Jakobs, +49 151 6894 7444
Fax: +49 (6132) 77 6601
press@boehringer-ingelheim.com
or
More information
www.boehringer-ingelheim.com

Link:

Multimedia Gallery

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release

- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release

With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp

Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release

The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev

7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release

MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release

Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye